Genomic profiling for defining luminal subtypes

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, explains the development of multigene tests, such as the Oncotype DX® Breast Cancer Assay and the PAM50 test, for classifying breast cancer into different subtypes. Luminal A and B subtypes of breast cancer may have important predictive value in the clinic.

This content is supported by Genomic Health, Inc.

Year of Production:
Running Time:
Color/Sound:

2015
01:24
Color/Sound

Comments are closed.